Integrity Solution to Meet FDA Audit Requirements WATERLOO, ON, June 28 /CNW/ - MKS Inc. (TSX:MKX), a leading provider of enterprise software configuration management (SCM) solutions for the Global 1000, today announced that TEVA Pharmaceuticals USA, the wholly-owned American subsidiary of TEVA Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and the leading manufacturer and distributor of generic drugs in the U.S., has selected the MKS Integrity Solution(R) for enterprise software configuration management (SCM). By securely automating IT change control and configuration management processes, TEVA will more effectively satisfy Pharmaceutical regulations such as the U.S. Food and Drug Administration's (FDA) 21 Code of Federal Regulations, Part 11 (21-CFR Part 11). Additional benefits that TEVA will realize from standardizing on the MKS Integrity Solution include: - Improved operational efficiencies from tighter integration between lines of business, development and IT operations. This is achieved through automation and enforcement of the linkage between change control and configuration management processes; - Traceability from requirements to the software assets promoted into production environments will provide improved management visibility, control, and metrics; - Enhanced cross-team communication and real-time collaboration improving software application quality, accuracy, reproducibility, and consistency; - Enforced version control processes to improve security of software assets and intellectual property; - Secure processes governing promotion to production will ensure no assets or artifacts are left behind as a change progresses through the lifecycle; and - More efficient roll backs or identification of all assets related to a change implemented at any point in the past. Tom Loane, Chief Information Officer for TEVA Pharmaceuticals USA, said, "One of the main measures for success in the implementation of the MKS Integrity Solution will be a reduction in the amount of paper and forms that get manually pushed from person to person. Simply automating service request forms and routing them via electronic workflows will result in a more effective use of time spent managing projects." The MKS Integrity Solution will initially be deployed in North Wales, Pennsylvania with future plans to deploy to other teams and locations world-wide. The future vision is to leverage MKS as the standard enterprise change control and configuration management solution for TEVA's global operations. About TEVA Pharmaceuticals USA TEVA Pharmaceuticals USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. Founded in 1901, Teva is Israel's largest pharmaceutical manufacturer and a global company operating in 19 countries on 5 continents. About MKS MKS Inc. ("MKS") (TSX: MKX) provides award-winning enterprise software configuration management (SCM) and interoperability software solutions enabling Global 1000 companies to better manage and control the complete process of software development. The company's family of SCM products offers advanced technology with robust workflow, version control, and impact analysis capabilities. Under its widely known MKS Toolkit brand, MKS also provides UNIX-Windows co-existence, and system administration that significantly cut development and administrative costs and reduce time to market while enabling enhanced performance. Founded in 1984 with over 10,000 customers worldwide, MKS has built its brand on the foundation of advanced technology, superior quality and extraordinary customer service. More information about MKS can be found at http://www.mks.com, or by calling 1-800-265-2797 (US & Canada), +49-711-351775-0 (Germany), and +44-1483-733900 (United Kingdom). Copyright (C) 2004 MKS Inc. MKS, MKS Integrity Solution and MKS Toolkit are registered trademarks of MKS Inc. All other trademarks mentioned in this release are the property of their respective owners. This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect the Company's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made including those factors detailed from time to time in filings made by the Company with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. The Company does not intend and does not assume any obligation to update these forward-looking statements. -0- 06/28/2004 /For further information: Media Contact: Alex Forbes, MKS Inc., Phone: (781) 359-3362, Email: aforbes(at)mks.com; To request a free copy of this organization's annual report, please go to http://www.newswire.ca and click on reports(at)cnw./ (MKX.) CO: MKS Inc. ST: Ontario IN: MLM CPR STW SU: CON -30- -0- Jun/28/2004 14:00 GMT
TEVA Pharmaceuticals USA to Standardize on MKS
Press spacebar to pause and continue. Press esc to stop.